Compare JBLU & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBLU | VRDN |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2002 | 2014 |
| Metric | JBLU | VRDN |
|---|---|---|
| Price | $5.26 | $19.24 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | $4.91 | ★ $35.46 |
| AVG Volume (30 Days) | ★ 29.6M | 2.3M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.83 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,062,000,000.00 | $5,706,000.00 |
| Revenue This Year | $12.11 | $13.73 |
| Revenue Next Year | $6.75 | $279.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.87 | $13.18 |
| 52 Week High | $6.46 | $34.29 |
| Indicator | JBLU | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 45.64 | 55.54 |
| Support Level | $4.54 | $17.54 |
| Resistance Level | $6.31 | $20.44 |
| Average True Range (ATR) | 0.30 | 0.84 |
| MACD | -0.09 | -0.08 |
| Stochastic Oscillator | 33.67 | 47.01 |
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.